Dynavax locks in new supply deal for vaccine component

Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a material definitive agreement with West Pharmaceutical Services, Inc. to secure the manufacture and supply of syringe stoppers for its HEPLISAV-B® vaccine. The new supply agreement, effective as of Monday, replaces a previous contract from July 27, 2016.

The contract stipulates that Dynavax must purchase set volumes of the product, which can be adjusted under certain conditions. The pricing is volume-dependent and may be revised in accordance with a specified price index. The agreement spans four years from the effective date with options for extension.

Both parties retain the right to terminate the agreement for reasons such as an uncured material breach or if either party faces insolvency, bankruptcy, or reorganization. Details of the supply agreement will be included in Dynavax's Annual Report on Form 10-K for the year ending December 31, 2024.

You May Also Be Interested In

• BiomX to rename itself Tessera Defense, ticker changes to HLSQ
• Kratos wins $20M contract for mobile SATCOM gateways in Asia
• Reitar Logtech converts $2.2M in promissory notes to shares